The long-acting monoclonal antibody clesrovimab (Enflonsia) was well tolerated in infants at increased risk for severe respiratory syncytial virus (RSV) disease through two RSV seasons.Among nearly 1,000 infants who received either a single dose of clesrovimab or monthly palivizumab (Synagis) in their first RSV season, adverse events were generally comparable between treatment groups.In the subset of nearly 300 children requiring ongoing RSV prevention in their second RSV season who got two doses of clesrovimab, adverse events were also comparable between those who had initially received clesrovimab or palivizumab in their first RSV season.
For respiratory syncytial virus (RSV) prevention, the long-acting monoclonal antibody clesrovimab (Enflonsia) was well tolerated among infants at increased risk for severe disease through two RSV seasons, a randomized clinical trial found.
In final results from the SMART trial, adverse events were generally comparable between infants who got a single 105-mg dose of clesrovimab or monthly palivizumab (Synagis) -- an older, short-acting monoclonal antibody that is now off the market -- in their first RSV season. The proportion with any adverse event was 75.3% versus 79.6%, respectively.
